Qiagen to transfer listing of shares to New York Stock Exchange

Qiagen has announced plans to transfer the US listing of its global shares to the New York Stock Exchange (NYSE), effective as of January 10th 2018.

The company is switching its listings from the NASDAQ Global Market to gain greater visibility within the healthcare sector and expand its global shareholder base, given that many of the firm's laboratory customers and pharmaceutical industry co-development partners are also listed on the NYSE.

Qiagen shares will continue to trade on the NASDAQ until the transfer is completed, after which they will retain the QGEN ticker. This will not affect the trading of Qiagen's global shares on the Frankfurt Stock Exchange under the ticker QIA.

Roland Sackers, chief financial officer of Qiagen, said: "This transfer will further raise the profile of Qiagen and the value of our brand for helping make improvements in life possible through our Sample to Insight molecular testing solutions."

The company provides solutions to over 500,000 customers around the world, and employs approximately 4,700 people across more than 35 locations worldwide.

With over 20 years of experience within the science market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current science roles we have available, you can search for the latest job roles, register your details, or contact the team today.